RxDoctor Payments Data

Jeffrey Yonce, MD

Family Medicine · Mount Pleasant, SCNPI 1417480518

Payments from drug & device makers

$12,832in general payments, 2019–2025

Across 658 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Amgen$936
  • Lilly USA, LLC$898
  • AstraZeneca$603
  • plus $6K from 42 others

What the payments were for

  • Food & beverage$12,823100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,832 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$174,743
Medicare patients
461
Services billed
2,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$100,483
FarxigaDapagliflozin Propanediol71$65,043
MounjaroTirzepatide52$63,897
EliquisApixaban64$56,157
JardianceEmpagliflozin52$52,570
JanuviaSitagliptin Phosphate33$34,810
WegovySemaglutide12$15,294
Repatha SureclickEvolocumab27$14,513
Repatha SyringeEvolocumab16$13,812
MyrbetriqMirabegron18$12,346
XareltoRivaroxaban11$11,561
Tresiba Flextouch U-200Insulin Degludec12$6,041
Synjardy XrEmpagliflozin/Metformin Hcl12$5,720
Rosuvastatin Calcium354$5,222
Atorvastatin Calcium371$3,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$1,474$115,77796 claims
AstraZenecaFarxiga$603$65,04371 claims
Lilly USA, LLCMounjaro$898$63,89752 claims
Boehringer IngelheimJardiance, Synjardy Xr$517$58,28964 claims
PfizerEliquis$1,511$56,15764 claims
MerckJanuvia$119$34,81033 claims
Astellas Pharma US IncMyrbetriq$232$12,34618 claims
Johnson & JohnsonXarelto$348$11,56111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Mount Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →